Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:600211's 5-Year Yield-on-Cost % is ranked better than 95.7% of 512
companies
in the Drug Manufacturers industry
Industry Median: 2.28
vs SHSE:600211: 23.22
Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Tibet Rhodiola Pharmaceutical Holding Co 5-Year Yield-on-Cost % Related Terms
SHSE:600211 vs ZTS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Tibet Rhodiola Pharmaceutical Holding Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tibet Rhodiola Pharmaceutical Holding Co 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tibet Rhodiola Pharmaceutical Holding Co's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Tibet Rhodiola Pharmaceutical Holding Co's 5-Year Yield-on-Cost % falls into.
Tibet Rhodiola Pharmaceutical Holding Co 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) has a 5-Year Yield-on-Cost % of 23.22 as of Aug. 12, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Tibet Rhodiola Pharmaceutical Holding Co and its competitors. This is 268% above median its historical median of 6.31. Over the past decade, Tibet Rhodiola Pharmaceutical Holding Co's 5-Year Yield-on-Cost % has ranged from 1.75 to 28.21. According to the industry distribution chart, Tibet Rhodiola Pharmaceutical Holding Co ranks #22 out of 512 companies in the Drug Manufacturers industry, placing it in the top 4.3%.
Is Tibet Rhodiola Pharmaceutical Holding Co's 5-Year Yield-on-Cost % too high?
Tibet Rhodiola Pharmaceutical Holding Co's current 5-Year Yield-on-Cost % of 23.22 is 268% above median its 10-year median of 6.31. Over the past 10 years, this metric has ranged from a low of 1.75 to a high of 28.21. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.28. Tibet Rhodiola Pharmaceutical Holding Co's value of 23.22 is 918.4% above this industry median. Based on the distribution chart, Tibet Rhodiola Pharmaceutical Holding Co ranks #22 out of 512 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Tibet Rhodiola Pharmaceutical Holding Co has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Tibet Rhodiola Pharmaceutical Holding Co's 5-Year Yield-on-Cost % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Tibet Rhodiola Pharmaceutical Holding Co ranks #22 out of 512 companies for 5-Year Yield-on-Cost %. This places Tibet Rhodiola Pharmaceutical Holding Co in the top 4% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 2.28. Tibet Rhodiola Pharmaceutical Holding Co's value of 23.22 is 918.4% above this benchmark. Historically, Tibet Rhodiola Pharmaceutical Holding Co's own 5-Year Yield-on-Cost % has ranged from 1.75 to 28.21 over the past decade. While the company's 10-year median is 6.31 vs. the industry median of 2.28, Tibet Rhodiola Pharmaceutical Holding Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.28, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tibet Rhodiola Pharmaceutical Holding Co's current 5-Year Yield-on-Cost % of 23.22 is 918.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Tibet Rhodiola Pharmaceutical Holding Co and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tibet Rhodiola Pharmaceutical Holding Co's current 5-Year Yield-on-Cost % is 23.22, which is 268% above median its own 10-year median of 6.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tibet Rhodiola Pharmaceutical Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) is currently considered Fairly Valued. The stock's GF Value™ is ¥39.69, compared to a current price of ¥39.89 — trading 0.5% above its estimated fair value. The current 5-Year Yield-on-Cost % is 23.22, which is 268% above median its 10-year median of 6.31 and 918.4% above the Drug Manufacturers industry median of 2.28. Tibet Rhodiola Pharmaceutical Holding Co's overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211), the current 5-Year Yield-on-Cost % is 23.22 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) Overvalued in 2026?
Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co stock appears to be overvalued.
The current stock price of ¥39.89 is trading 0.5% above its estimated GF Value™ of ¥39.69.
GuruFocus considers Tibet Rhodiola Pharmaceutical Holding Co to be Fairly Valued.
Key valuation signals for SHSE:600211:
5-Year Yield-on-Cost %: 23.22 (268% above median its 10-year median of 6.31)
GF Value™: ¥39.69 vs. price of ¥39.89 (0.5% above fair value)
Industry Position: 918.4% above the Drug Manufacturers median (#22 of 512)
No single metric tells the full story. See the SHSE:600211 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tibet Rhodiola Pharmaceutical Holding Co is a pharmaceutical company engaged in the production and sales of capsules, biological agents, granules, and coatings. The company's products cover biopharmaceuticals, Tibetan medicine, traditional Chinese medicine, and chemical drugs, involving fields such as cardiovascular and cerebrovascular diseases, hepatobiliary diseases, orthopedic pain relief, rheumatism, and cold medicines.
87GF Score
Get the complete analysis for SHSE:600211
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600211 has been successfully added to your 
